ArticleAmerican journal of translational research2026
Inhibition of CDC42 in adenomyosis reduces the proliferation of endometrial stromal cells and the migration of epithelial cells.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAdenomyosis severely impairs fertility and quality of life. This study investigated the pathophysiologic role of cell division cycle 42 (CDC42) in adenomyosis by profiling its expression, identifying its binding partners, and performing functional assays on endometrial cells.
methodsImmunofluorescence was used to evaluate CDC42 expression in endometrial cells from adenomyosis patients. RNA sequencing (RNA-seq) was used to analyze transcriptomic changes following CDC42 knockdown. The effects of CDC42 inhibition on endometrial stromal cell proliferation and migration were assessed using cell viability and migration assays. Furthermore, coimmunoprecipitation coupled with mass spectrometry (Co-IP/MS) was conducted to identify CDC42-interacting proteins. Finally, conditioned medium from CDC42-knockdown stromal cells was used to evaluate the effects of paracrine signaling on endometrial epithelial cell migration.
resultsCDC42 expression was significantly upregulated in the endometrial cells of adenomyosis patients. Transcriptomic analysis revealed that CDC42 knockdown downregulated the expression of genes associated with the cell cycle and cytokine signaling. Functionally, CDC42 inhibition markedly reduced stromal cell proliferation and attenuated the migration of both stromal and epithelial cells. Notably, conditioned medium from CDC42-knockdown cells also suppressed epithelial cell migration. Co-IP/MS revealed 70 CDC42-interacting proteins, and subsequent Gene Ontology (GO) enrichment analysis indicated their primary involvement in mRNA metabolism, cell adhesion, and Rho GTPase signaling pathways.
conclusionsCDC42 contributes to the pathogenesis of adenomyosis by promoting endometrial stromal cell proliferation and epithelial cell migration, likely by mediating cell cycle regulation and Rho GTPase signaling networks. Therefore, targeting CDC42 is a promising therapeutic strategy for the management of adenomyosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.